{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:33:00Z","timestamp":1787995980790,"version":"build-2784847793"},"reference-count":28,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:p>Background: Immunotherapies targeting \u03b1-synuclein aim to limit its extracellular spread in the brain and prevent progression of pathology in Parkinson\u2019s disease (PD). PD03A is a specific active immunotherapy (SAIT) involving immunization with a short peptide formulation. Objective: This phase 1 study characterized the safety and tolerability of PD03A in patients with early PD. A key secondary objective was to evaluate immunological activity following immunization. Methods: This was a phase 1 study of two different doses of PD03A versus placebo in PD patients. Patients were randomized (1:1:1) to receive four priming plus one booster vaccination of PD03A 15\u03bcg, PD03A 75\u03bcg or placebo and were followed for 52 weeks. Results: Overall, 36 patients were randomized, of which 35 received five immunizations and completed the study. All patients experienced at least one adverse event. Transient local injection site reactions affected all but two patients; otherwise most AEs were considered unrelated to study treatment. A substantial IgG antibody response against PD03 was observed with a maximum titer achieved at Week-12. Differences in titers between both active groups versus placebo were statistically significant from the second immunization at Week-8 until Week-52. Conclusion: The safety profile and positive antibody response of PD03A supports the further development of active immunotherapeutic approaches for the treatment of PD.<\/jats:p>","DOI":"10.3233\/jpd-212594","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T16:18:44Z","timestamp":1622564324000},"page":"1079-1089","source":"Crossref","is-referenced-by-count":53,"title":["Safety and Tolerability of Active Immunotherapy Targeting \u03b1-Synuclein with PD03A in Patients with Early Parkinson\u2019s Disease: A Randomized, Placebo-Controlled, Phase 1 Study"],"prefix":"10.1177","volume":"11","author":[{"given":"Werner","family":"Poewe","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the AFF011 investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"AFF011 study investigators:","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Volc","sequence":"additional","affiliation":[{"name":"PROSENEX Study Center at Privatklinik Confraternitaet, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Seppi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Medori","sequence":"additional","affiliation":[{"name":"AFFiRiS AG, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"L\u00fchrs","sequence":"additional","affiliation":[{"name":"AFFiRiS AG, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kutzelnigg","sequence":"additional","affiliation":[{"name":"AFFiRiS AG, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atbin","family":"Djamshidian","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Thun-Hohenstein","sequence":"additional","affiliation":[{"name":"PROSENEX Study Center at Privatklinik Confraternitaet, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassilios G.","family":"Meissner","sequence":"additional","affiliation":[{"name":"Service de Neurologie, CRMR Atrophie Multisyst\u00e9matis\u00e9e, CHU Bordeaux and Universit\u00e9 Bordeaux, CNRS, IMN, UMR 5293, F-33000 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[{"name":"Toulouse Parkinson Expert Center, Departments of Neurosciences and Clinical Pharmacology, Centre d\u2019Investigation Clinique de Toulouse CIC1436, NS-Park\/FCRIN Network, and NeuroToul COEN Center, University Hospital of Toulouse, INSERM, University of Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Schneeberger","sequence":"additional","affiliation":[{"name":"AFFiRiS AG, Vienna, Austria"},{"name":"Accanis GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Staffler","sequence":"additional","affiliation":[{"name":"AFFiRiS AG, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Seppi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atbin","family":"Djamshidian","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"deMarzi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Heim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Mangesius","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaela","family":"Stolz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Wachowicz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Volc","sequence":"additional","affiliation":[{"name":"PROSENEX Study Center at Privatklinik Confraternitaet, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Thun-Hohenstein","sequence":"additional","affiliation":[{"name":"PROSENEX Study Center at Privatklinik Confraternitaet, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Riha","sequence":"additional","affiliation":[{"name":"PROSENEX Study Center at Privatklinik Confraternitaet, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Schneeberger","sequence":"additional","affiliation":[{"name":"AFFiRiS AG, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"B\u00fcrger","sequence":"additional","affiliation":[{"name":"AFFiRiS AG, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergana","family":"Galabova","sequence":"additional","affiliation":[{"name":"AFFiRiS AG, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-212594_ref1","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1172\/JCI66029","article-title":"Thinking laterally about neurodegenerative proteinopathies","volume":"123","author":"Golde","year":"2013","journal-title":"J Clin Invest"},{"key":"10.3233\/JPD-212594_ref2","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.3233\/JPD-212594_ref3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jnc.14808","article-title":"alpha-synuclein oligomers and fibrils: A of species, a spectrum of toxicities","volume":"150","author":"Alam","year":"2019","journal-title":"J Neurochem"},{"key":"10.3233\/JPD-212594_ref4","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1093\/brain\/awz296","article-title":"Intrastriatal alpha-synuclein fibrils in monkeys: Spreading, imaging and neuropathological changes","volume":"142","author":"Chu","year":"2019","journal-title":"Brain"},{"key":"10.3233\/JPD-212594_ref5","doi-asserted-by":"crossref","first-page":"E5308","DOI":"10.1073\/pnas.1514475112","article-title":"Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism","volume":"112","author":"Prusiner","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JPD-212594_ref6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40035-019-0172-x","article-title":"Beyond the synucleinopathies: Alpha synuclein as a driving force in neurodegenerative comorbidities","volume":"8","author":"Visanji","year":"2019","journal-title":"Transl Neurodegener"},{"key":"10.3233\/JPD-212594_ref7","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajpath.2012.11.018","article-title":"Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alpha-synuclein","volume":"182","author":"Games","year":"2013","journal-title":"Am J Pathol"},{"key":"10.3233\/JPD-212594_ref8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1471-4159.2008.05612.x","article-title":"Controlling the mass action of alpha-synuclein in Parkinson\u2019s disease","volume":"107","author":"Kim","year":"2008","journal-title":"J Neurochem"},{"key":"10.3233\/JPD-212594_ref9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2013.01.013","article-title":"Immunotherapy for neurodegenerative diseases: Focus on alpha-synucleinopathies","volume":"138","author":"Valera","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.3233\/JPD-212594_ref10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","article-title":"Therapeutic approaches to target alpha-synuclein pathology","volume":"298","author":"Brundin","year":"2017","journal-title":"Exp Neurol"},{"key":"10.3233\/JPD-212594_ref11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1126\/science.aai8231","article-title":"Can immunotherapy treat neurodegeneration?","volume":"357","author":"Schwartz","year":"2017","journal-title":"Science"},{"key":"10.3233\/JPD-212594_ref12","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/13543784.2020.1771693","article-title":"Immunization therapies for Parkinson\u2019s disease: State of the art and considerations for future clinical trials","volume":"29","author":"Antonini","year":"2020","journal-title":"Expert Opin Invest Drugs"},{"key":"10.3233\/JPD-212594_ref13","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson disease: A randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-212594_ref14","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-alpha-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212594_ref15","doi-asserted-by":"crossref","first-page":"104587","DOI":"10.1016\/j.nbd.2019.104587","article-title":"Immunotherapy in Parkinson\u2019s disease: Current status and future directions","volume":"132","author":"Chatterjee","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.3233\/JPD-212594_ref16","unstructured":"Pagano G , Taylor K , Cabrera J , Marchesi M , Zago W , Tripuraneni R , Boulay A , Vogt A , Boess F , Nikolcheva T , Svoboda H , Britschgi M , Lipsmeier F , Lindemann M , Dziadek S , Azulay J , Mollenhauer B , Manzanares L , Russell D , Boyd J , Nicholas A , Luquin M , Hauser RA , Simuni T , Gasser T , Poewe W , Kinney G , Doody R , Fontoura P , Umbricht D , Bonni A (2020) PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson\u2019s disease; Part 1 Week-52 results [abstract]. Mov Disord 35 (Suppl 1), https:\/\/www.mdsabstracts.org\/abstract\/pasadena-a-phase-2-study-to-evaluate-the-safety-and-efficacy-of-prasinezumab-in-early-parkinsons-disease-part-1-week-52-results\/. Accessed April 23, 2021."},{"key":"10.3233\/JPD-212594_ref17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the alpha-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: A randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-212594_ref18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: Implications for Parkinson\u2019s disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JPD-212594_ref19","doi-asserted-by":"crossref","first-page":"948","DOI":"10.4161\/hv.6.11.13217","article-title":"AFFITOME(R) technology in neurodegenerative diseases: The doubling advantage","volume":"6","author":"Schneeberger","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.3233\/JPD-212594_ref20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: A clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-212594_ref21","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212594_ref22","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/mds.21596","article-title":"The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: Results from an international pilot study","volume":"22","author":"Chaudhuri","year":"2007","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212594_ref24","doi-asserted-by":"crossref","unstructured":"Guy W (1976) Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology Department of Health, Education, and Welfare, Washington, DC., Rockville, MD, pp. 218\u2013222.","DOI":"10.1037\/e591322011-001"},{"key":"10.3233\/JPD-212594_ref25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity","volume":"141","author":"McNeil","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.3233\/JPD-212594_ref26","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"New Engl J Med"},{"key":"10.3233\/JPD-212594_ref27","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/mds.28218","article-title":"A phase 1 randomized trial of specific active \u03b1-synuclein immunotherapies PD01A and PD03A in multiple system atrophy","volume":"11","author":"Meissner","year":"2020","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-212594_ref28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaut.2007.07.007","article-title":"Homeostatic roles of naturally occurring antibodies: An overview","volume":"29","author":"Lutz","year":"2007","journal-title":"J Autoimmun"},{"key":"10.3233\/JPD-212594_ref29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13024-017-0187-7","article-title":"Autoimmune antibody decline in Parkinson\u2019s disease and Multiple System Atrophy; a step towards immunotherapeutic strategies","volume":"12","author":"Brudek","year":"2017","journal-title":"Mol Neurodegener"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-212594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:49:58Z","timestamp":1777610998000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-212594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":28,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jpd-212594","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]}}}